June 22 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO :
* AURINIA COMPLETES PATIENT ENROLLMENT INTO THE AUDREY PHASE 2/3 CLINICAL TRIAL OF VOCLOSPORIN OPHTHALMIC SOLUTION FOR THE TREATMENT OF DRY EYE SYNDROME
* AURINIA PHARMACEUTICALS INC - VOCLOSPORIN OPHTHALMIC SOLUTION (VOS) RESULTS ANTICIPATED IN Q4 OF 2020